EGFR

Introduction The treatment landscape for non-small cell lung cancer (NSCLC) has changed dramatically over the past decade. For patients whose tumors carry specific EGFR (Epidermal Growth Factor Receptor) mutations, targeted therapies have significantly improved survival and quality of life compared with traditional chemotherapy. Among these targeted treatments, Osimertinib has become the preferred first-line treatment for […]

Introduction For many patients with EGFR-mutated non-small cell lung cancer (NSCLC), targeted therapy has transformed treatment outcomes. Earlier EGFR inhibitors helped many patients control their cancer for months or even years. However, over time, some cancers develop resistance, making these medicines less effective. One of the most common resistance mechanisms is the EGFR T790M mutation.